Caitlin Koris

Pharmaceutical market researcher for @DRGinsights - providing updated market news and insights on cardiovascular, metabolic and renal disorder treatments.

[Caitlin Koris @CKoris_DRG]

#KidneyWk is fast approaching! https://t.co/Br37IiMciy

[Caitlin Koris @CKoris_DRG]

#obesity estimates https://t.co/fO9qYWXgpq

[Clarivate Epidemiology @DRG_Epi]

#DRG estimates prevalence of #obesity highest in Hong Kong, lowest in Philippines @DRGinsights

[Caitlin Koris @CKoris_DRG]

Learn more from @jkhanDRG during #diabetesweek on GLP-1 RAs https://t.co/YM54zQqVZn

[Caitlin Koris @CKoris_DRG]

How will U.S. payers handle gene therapy? Learn more: https://t.co/4d1pP6dF1z

[Caitlin Koris @CKoris_DRG]

Almost #diabetesweek! Learn more about unmet need within diabetic kidney disease https://t.co/jJzkxWg94u

[Caitlin Koris @CKoris_DRG]

Insights from expert @TBlackstock_DRG - the #dyslipidemia market will grow more than $7 billion by 2025 https://t.co/m8kXNcI0GY

[Caitlin Koris @CKoris_DRG]

Bypassing Regulatory Hurdles for Faster Access to New Drugs?... Potential Disaster! | DRG Blog | DRG https://t.co/Mvvv9LUaOY

[Caitlin Koris @CKoris_DRG]

60% of surveyed physicians believe drug treatment for #hyperkalemia should be initiated between 5.1 - 6 mEq/L. Learn more from @jkhanDRG https://t.co/xJOleLHyGy

[Jihan Khan @jkhanDRG]

Nephrologists Report Robust Veltassa Uptake for Hyperkalemia Treatment | Drug Watch | DRG https://t.co/886QgOrcBN

[Dan Diamond @ddiamond]

Just out — U.S. uninsured rate fell below 9 percent for first time.

Only 8.6 percent of Americans uninsured per new CDC data. Historic low.

[Caitlin Koris @CKoris_DRG]

Galenica to buy biotech firm Relypsa for $1.5 billion, ahead of split https://t.co/jA1i8Gr7y2 via @Reuters

[Caitlin Koris @CKoris_DRG]

Surveyed UK nephrologists report lowest IV iron use within EU- learn more about prescribing practices from @DRGinsights #anemia #CKD

[Caitlin Koris @CKoris_DRG]

Insights into emerging HIF-PH inhibitors #DRG #anemia https://t.co/Gt0Vn9SGle

[Jihan Khan @jkhanDRG]

Will HIF-PH Inhibitors Be The Future of Renal Anemia Treatment? Nephrologists and Payers Weigh In – DRG Blog – DRG https://t.co/HcBCcdmMZw

[Caitlin Koris @CKoris_DRG]

@ViforPharma partnerships keep growing! @Roche #Mircera, @Relypsa #Veltassa, #OPKO #Rayaldee and... @ChemoCentryxInc https://t.co/0Lh8C2roAC

[Biotechnology @biotechnolog_dp]

Vifor pays $110M upfront for EU rights to late-phase renal disease drugs - FierceBiotech #rights https://t.co/0LMdyb95CS

[Caitlin Koris @CKoris_DRG]

Access? Prescribing patterns? Market share? #DRG has you covered https://t.co/S2cLqOUGSR

[Caitlin Koris @CKoris_DRG]

@Renal_DRG https://t.co/T2nkJern53

[Caitlin Koris @CKoris_DRG]

#Renvela to #Velphoro- are physicians switching their choice of phosphate binder? Insights from this year's spring clinical meetings at #NKF

[Caitlin Koris @CKoris_DRG]

"But...when you're dealing with a market where you need to build it, it’s a market that’s going to take time." #Relypsa #hyperkalemia

[Caitlin Koris @CKoris_DRG]

@Renal_DRG https://t.co/fQL7Yc531I

[Caitlin Koris @CKoris_DRG]

NKF spring clinical meeting draws huge crowds at hyperkalemia talk. What is the buzz?? #hyperkalemia #NKF2016